

## AMENDMENTS TO THE DRAWINGS

Replace Drawing Sheet 11/11 for Figure 11 with the Replacement Sheet for Figure 11 submitted herewith.

## REMARKS

The title of the invention has been amended and the specification has been amended to cross-reference related applications.

In addition, the recitation of the Onimaru et al. (Circ. Res. 91:923-930, 2002) reference has been amended throughout the specification to correct a typographical error. The specification has also been amended to correct a typographical error in the spelling of the word “inhibitory” in the paragraph beginning at page 27, line 16, of the English language specification.

The recitation, at page 26 of the English language specification, of “doses of adenoviruses” has been amended to “doses of adenoviral vectors” and “doses of minus strand RNA viruses” has been amended to “doses of minus strand RNA virus vectors.” These amendments are supported by the context of the preceding sentence.

Further, Figure 11 has been amended as shown in the Annotated Sheet submitted herewith. Support for this amendment is found, for example, at page 36, lines 18-20, of the English language specification.

No new matter has been added by the present amendments.


A courtesy copy of the present specification is enclosed, but the World Intellectual Property Office (WIPO) copy should be relied upon if it is already present in the U.S. Patent and Trademark Office file.

If there are any charges or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully submitted,

Date: 15-Sep-2006



James D. DeCamp, Ph.D.  
Reg. No. 43,580

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045